CHA2DS2-VASc Calculator

Atrial fibrillation lets blood pool in the upper chambers of the heart, where clots can form and travel to the brain. The 2024 European guideline puts the increase in ischemic stroke risk at about five-fold and links about one in every five strokes to AF. Anticoagulants lower that risk but raise the risk of bleeding, so the practical question is who benefits enough to take one. A CHA2DS2-VASc calculator answers the first half of that question by sorting patients into groups with known average stroke rates.

Two sister tools cover related checks for people with AF. The eGFR Calculator estimates kidney function, which guidelines ask clinicians to check before and during treatment with the newer anticoagulants, and the QTc Calculator corrects the QT interval, which is monitored when a drug that can prolong it is started, including antiarrhythmic drugs such as sotalol and dofetilide.

What the score measures and who it is for

Lip and colleagues introduced the score in 2010 as a refinement of an earlier British scheme and tested it on 1,084 patients from the Euro Heart Survey on Atrial Fibrillation. Its main gain over the older CHADS2 score was at the low end: patients the new score called low risk had no thromboembolic events in that cohort, and far fewer patients landed in the vague intermediate group (15.1% instead of 61.9% with CHADS2).

The score applies to AF and atrial flutter in people who do not have moderate to severe mitral stenosis or a mechanical heart valve. It applies equally to paroxysmal, persistent and permanent AF, because guidelines base stroke prevention on risk, not on how often the rhythm comes and goes.

The point table and the formula

Each letter of the acronym is one item. Two items count double, which is what the subscript 2 in the name refers to:

Age counts once: 1 point from 65 to 74 or 2 points from 75 on, never both, so the maximum is 9. Of the 192 possible combinations of sex, age group and the five conditions, exactly one scores 0 (a man under 65 with none of them) and exactly one scores 9.

Worked example: a 68-year-old woman with high blood pressure

She gets 1 point for hypertension, 1 for age 65 to 74 and 1 for female sex, a CHA2DS2-VASc score of 3. Her CHA2DS2-VA score is 2 and her CHADS2 score is 1, since CHADS2 counts only age 75 and up. In the Swedish cohort, patients with a score of 3 who never used an anticoagulant had ischemic strokes at 3.2% per year and any stroke, TIA or embolism at 4.6% per year. Because 3 is the high tier for women, the 2023 US guideline recommends anticoagulation, and the European guideline reaches the same answer through her CHA2DS2-VA score of 2. This is the profile the calculator loads by default.

Second example: a 58-year-old man with diabetes

Diabetes is his only item, so his score is 1 under all three systems. A score of 1 is the intermediate tier for men, with an estimated risk of about 1% to 2% a year: the US guideline calls anticoagulation reasonable and suggests weighing risk modifiers such as AF burden and blood pressure control, while the European guideline says it should be considered. The Swedish cohort recorded 0.6% per year for ischemic stroke at this score. The older CHADS2 data put a score of 1 at 2.8 strokes per 100 patient-years, a gap that shows how much the populations behind each table differ.

Annual stroke rate at each CHA2DS2-VASc score

The table combines two published sources. The middle columns are unadjusted rates among 90,490 Swedish patients who never used an anticoagulant during follow-up; the last column is the adjusted stroke rate from Lip and colleagues that the 2014 AHA/ACC/HRS guideline reproduced.

Rates are events per 100 patient-years, which reads as percent per year. The Swedish rates rise steadily up to a score of 7. Above that, too few patients reach the highest scores for the estimates to be smooth, and the 2014 guideline warns that rates in contemporary cohorts may differ from its table.

Scores by age, sex and conditions at a glance

This lookup table was computed with the same rules as the calculator. Each cell shows the CHA2DS2-VASc total and the 2023 US risk tier (low, interm. for intermediate, or high) for that sex.

Moving right along a row, age raises the tier until it reaches high, while switching between the man and woman columns changes the score but never the tier. A woman under 65 with no other condition scores 1, the lowest score a woman can have, and is still in the low tier.

How US and European guidelines use the score

The 2023 ACC/AHA/ACCP/HRS guideline recommends evaluating every patient with AF with a validated score such as CHA2DS2-VASc and frames the decision around estimated annual risk: low below about 1%, intermediate at about 1% to 2% and high above about 2%. Anticoagulation is recommended in the high tier (Class 1) and reasonable in the intermediate tier (Class 2a), and aspirin alone is not recommended as a substitute. The guideline also stresses that the same score can mean different risks in different populations: across 15 cohorts, a score of 2 corresponded to under 1% a year in four, 1% to 2% in six and more than 2% in five.

The 2024 ESC guideline drops the sex point altogether. It calls female sex an age-dependent stroke risk modifier rather than a risk factor and notes that earlier guidelines effectively used CHA2DS2-VA anyway by setting higher thresholds for women. Anticoagulation is recommended at a CHA2DS2-VA score of 2 or more and should be considered at 1. In practice the two guidelines agree: across all 192 combinations the calculator can produce, the US tier and the European category point the same way.

CHADS2 and CHA2DS2-VASc compared

CHADS2, published by Gage and colleagues in 2001, gives 1 point each for heart failure, hypertension, age 75 or older and diabetes and 2 points for prior stroke or TIA. It was validated in the National Registry of Atrial Fibrillation, 1,733 Medicare beneficiaries aged 65 to 95 who were not prescribed warfarin, where its stroke rates per 100 patient-years were:

Take a 79-year-old man with heart failure, hypertension and a prior TIA. His CHADS2 score is 5 (12.5 per 100 patient-years in the registry) and his CHA2DS2-VASc score is 6, which matched an ischemic stroke rate of 9.7% per year in the Swedish cohort. Both scores flag him as high risk. The difference shows at the low end, where CHA2DS2-VASc adds age 65 to 74, vascular disease and sex and separates patients that CHADS2 lumps together at 0 or 1.

How to use this calculator

Pick the age group and sex, then tick each diagnosed condition. Count hypertension even when treatment keeps the readings normal, and count a TIA even if symptoms cleared within minutes. The red card shows the total, the US tier, the CHA2DS2-VA and CHADS2 scores and the Swedish annual rates; the cards below explain both guidelines, show where each point came from and highlight your row in the rate table.

Who this calculator is for

It is built for medical and nursing students learning stroke prevention, for clinicians who want a quick cross-check of all three scores, and for patients and family members who want to understand a number mentioned at an appointment. It is not a tool for starting or stopping a medicine on your own.

Key terms

• Atrial fibrillation (AF): an irregular, often fast heart rhythm in which the atria quiver instead of contracting.
• Thromboembolism: a clot that forms in one place and blocks an artery elsewhere, such as in the brain.
• TIA: transient ischemic attack, a brief stroke-like episode that resolves without lasting damage but signals high risk.
• Anticoagulant: a drug that slows clotting; the direct oral anticoagulants (apixaban, dabigatran, edoxaban, rivaroxaban) or warfarin.
• Risk modifier: a factor that shifts risk within a score level without earning points, such as AF burden or blood pressure control.
• C-statistic: how well a score separates people who have events from those who do not, from 0.5 (chance) to 1.0 (perfect).

What changes the score, and tips for using it

• Birthdays: turning 65 adds a point and turning 75 adds another, with no change in health at all.
• New diagnoses: diabetes, heart failure, a heart attack or a TIA each add points, and a stroke adds two.
• Reassessment: the US guideline asks for periodic review, typically once a year, and sooner when health changes.
• Blood pressure control: it does not change the score, but the US guideline lists it, along with AF burden, among the risk modifiers worth weighing when the estimated risk is low to intermediate.
• Bring the details: dates of past strokes, imaging reports and medication lists make the score more accurate than memory alone.

Limitations

CHA2DS2-VASc discriminates only moderately: its c-statistic was 0.67 for thromboembolism in the Swedish cohort and 0.606 in the original study. It ignores kidney disease, AF burden, left atrial size, cancer and biomarkers such as troponin and natriuretic peptides, which the guidelines treat as risk modifiers. Some conditions, such as hypertrophic cardiomyopathy, call for anticoagulation whatever the score says, and the score says nothing about bleeding.

Related calculators

• Kidney function for anticoagulant dosing: eGFR Calculator.
• Corrected QT interval during rhythm-control treatment: QTc Calculator.
• For people with AF and a BMI above 27, the US guideline recommends losing at least 10% of body weight to reduce AF burden: BMI Calculator and Weight Loss Calculator.

Sources

• Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010). Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 137:263-272. PubMed
• Friberg L, Rosenqvist M, Lip GY (2012). Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. European Heart Journal 33:1500-1510. PubMed
• Gage BF, Waterman AD, Shannon W, et al. (2001). Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:2864-2870. PubMed
• Joglar JA, Chung MK, et al. (2024). 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. Circulation 149:e1-e156. Full text (PubMed Central)
• Van Gelder IC, Rienstra M, et al. (2024). 2024 ESC Guidelines for the management of atrial fibrillation. European Heart Journal 45:3314-3414. PubMed
• January CT, Wann LS, et al. (2014). 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation, Table 7. Circulation 130:e199-e267. PubMed